Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Contemp Clin Trials. 2010 Jun 2;31(5):473–482. doi: 10.1016/j.cct.2010.05.010

Table 5.

Percentages of each dose levels recommended as MTD in different scenarios.a

Scenario Dose levelb Probability of DLTs for the dose ANETS for the dose Percentages (%) the dose chosen as MTD

EIDc IDd Standardd CRMd
Target-Scenario 1 0.08 0.34 12 16 45 10
2 0.24 0.43 33 34 33 34
3 0.33 0.48 35 34 17 35
4 0.44 0.54 17 14 4 19
5 0.56 0.61 3 2 0.4 2
6 0.76 0.71 0.1 0 0 0
Under-Toxic-Scenario 1 0.08 0.27 37 16 45 10
2 0.24 0.36 15 34 33 34
3 0.33 0.41 30 34 17 35
4 0.44 0.48 36 14 4 19
5 0.56 0.56 15 2 0.4 2
6 0.76 0.67 1 0 0 0
Over-Toxic-Scenario 1 0.08 0.41 36 16 45 10
2 0.24 0.49 40 34 33 34
3 0.33 0.53 20 34 17 35
4 0.44 0.59 4 14 4 19
5 0.56 0.65 0.3 2 0.4 2
6 0.76 0.75 0 0 0 0
a

DLT: dose limiting toxicity. MTD: maximum tolerated dose. EID: extended isotonic design. ID: isotonic design. ANETS: averaged normalized equivalent toxicity score.

b

The dose level in bold and with underline is the true MTD.

c

Designs treating toxicity response as quasi-continuous variable is targeted with TNETS≤0.476.

d

Designs treating toxicity response as binary variable is targeted with TTL≤0.33.